JP7599727B2 - マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット - Google Patents

マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット Download PDF

Info

Publication number
JP7599727B2
JP7599727B2 JP2022519804A JP2022519804A JP7599727B2 JP 7599727 B2 JP7599727 B2 JP 7599727B2 JP 2022519804 A JP2022519804 A JP 2022519804A JP 2022519804 A JP2022519804 A JP 2022519804A JP 7599727 B2 JP7599727 B2 JP 7599727B2
Authority
JP
Japan
Prior art keywords
therapeutic
compound
diagnostic
dextran
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550174A5 (https=
JP2022550174A (ja
Inventor
エイ． ラルフ、デイビッド
アーノルド、ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of JP2022550174A publication Critical patent/JP2022550174A/ja
Publication of JP2022550174A5 publication Critical patent/JP2022550174A5/ja
Application granted granted Critical
Publication of JP7599727B2 publication Critical patent/JP7599727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2022519804A 2019-09-30 2020-09-30 マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット Active JP7599727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908136P 2019-09-30 2019-09-30
US62/908,136 2019-09-30
PCT/US2020/053604 WO2021067479A1 (en) 2019-09-30 2020-09-30 Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands

Publications (3)

Publication Number Publication Date
JP2022550174A JP2022550174A (ja) 2022-11-30
JP2022550174A5 JP2022550174A5 (https=) 2023-09-28
JP7599727B2 true JP7599727B2 (ja) 2024-12-16

Family

ID=75337533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519804A Active JP7599727B2 (ja) 2019-09-30 2020-09-30 マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット

Country Status (7)

Country Link
US (1) US20210145989A1 (https=)
EP (1) EP4021459A4 (https=)
JP (1) JP7599727B2 (https=)
CN (1) CN115151264B (https=)
CA (1) CA3155675A1 (https=)
MX (1) MX2022003699A (https=)
WO (1) WO2021067479A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) * 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
CN114894698B (zh) * 2022-04-15 2023-02-03 广东省第二人民医院（广东省卫生应急医院） MDSCs在再生障碍性贫血诊断和/或分型中的应用
EP4554984A1 (en) * 2022-07-13 2025-05-21 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169883A1 (en) 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
JP2006098265A (ja) 2004-09-30 2006-04-13 Shimadzu Corp 試料の解析方法
JP2016527252A (ja) 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624046A (en) * 1982-01-04 1986-11-25 Fairchild Camera & Instrument Corp. Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
JP3582234B2 (ja) * 1996-05-20 2004-10-27 ニプロ株式会社 ＩｇＡ腎症特異的フィブロネクチン断片、その検出方法およびキット
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
AU2003267872A1 (en) * 2002-05-06 2003-11-11 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US20080193372A1 (en) * 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
US20080004237A1 (en) * 2006-02-23 2008-01-03 Tam Joemy C Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers
WO2012171035A1 (en) * 2011-06-10 2012-12-13 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
CA3064277A1 (en) * 2017-05-19 2018-11-22 Navidea Biopharmaceuticals, Inc. Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169883A1 (en) 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
JP2006098265A (ja) 2004-09-30 2006-04-13 Shimadzu Corp 試料の解析方法
JP2016527252A (ja) 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Zhengtao QIN et al.，"Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept"，Journal of Nuclear Medicine，2019年02月22日，Vol.60，No.9，p.1325-1332，DOI: 10.2967/jnumed.118.223727
Zohreh VARASTEH et al.，"Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept"，EJNMMI Research，2017年，Vol.7，40，p.1-9，DOI: 10.1186/s13550-017-0287-y

Also Published As

Publication number Publication date
CA3155675A1 (en) 2021-04-08
WO2021067479A1 (en) 2021-04-08
US20210145989A1 (en) 2021-05-20
CN115151264B (zh) 2024-03-12
JP2022550174A (ja) 2022-11-30
EP4021459A4 (en) 2023-09-27
MX2022003699A (es) 2022-07-13
EP4021459A1 (en) 2022-07-06
CN115151264A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7599727B2 (ja) マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット
JP2025013502A (ja) 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法
ES2788865T3 (es) Conjugados farmacéuticos de nanopartículas
US11559591B2 (en) Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
CA2955438A1 (en) Dextran conjugates for targeting macrophages and other mannose binding c-type lectin receptor expressing cells
US12178829B2 (en) Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
JP7665206B2 (ja) マクロファージの表現型を改変するための組成物および方法
JP2016528299A (ja) ビタミンｂ１２および内因子を含む組成物およびその使用方法
WO2020055455A1 (en) Targeted nanoparticles for diagnosing, detecting, and treating cancer
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
ES2784182T3 (es) Composiciones y métodos para inducir la apoptosis
US20210052639A1 (en) Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20230302041A1 (en) Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
US20250382392A1 (en) Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
WO2023076220A1 (en) Conjugates having antifouling nanoparticles and methods of use
JP2025523813A (ja) ペイロードをｃｄ２０６発現細胞に対して標的化する分解可能なジスルフィド／炭酸塩リンカーを有するマンノシル化アミンデキストラン薬物送達ビヒクル
BR122024008143A2 (pt) Uso de conjugados de nanopartículas para tratamento de tumor cerebral

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7599727

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150